Patient-based mouse models to find better treatments for chronic myelomonocytic leukemia
Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia
Researchers are using mice implanted with patients' CMML cells to try out new treatment approaches for people with chronic myelomonocytic leukemia.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11179159 on NIH RePORTER |
What this research studies
I have CMML, and the team makes mouse models using actual patient leukemia cells so the disease behaves more like it does in people. They have built models from samples of 92 patients using immune-deficient mice engineered to support human blood cells. The next step is to add small mast cell clones found in about 20% of patients to create hybrid models and study how the different cell clones interact. These hybrid models will be used to try drugs that target abnormal cytokine signaling and mRNA splicing seen in specific genetic subgroups.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with CMML, especially those willing to donate blood or bone marrow samples or whose disease includes a small mast cell component.
Not a fit: People without CMML or those seeking immediate treatment effects should not expect direct clinical benefit from this laboratory-based modeling work.
Why it matters
Potential benefit: If successful, this work could help identify more effective, personalized treatments for CMML patients.
How similar studies have performed: Researchers have already created CMML patient-derived xenografts and used them to find promising targets, while adding mast cell clones to make hybrid models is a new and untested advance.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Padron, Eric — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Padron, Eric
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.